Tuesday, BridgeBio Pharma Inc (NASDAQ:BBIO) announced sustained results from the PROPEL 2 Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia, a disorder of bone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results